Phase 4 N=336 Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue
Multiple Sclerosis
Primary: Change in the Modified Fatigue Impact Scale (MFIS) Score — -15.2; -16.0; -17.3 score on a scale — p=0.3451
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=25 Eszopiclone for the Treatment of Posttraumatic Stress Disorder
Posttraumatic Stress Disorders
Primary: Change in Symptoms of Post-Traumatic Stress Disorder (PTSD) Between Baseline and Week 12 — -23; -20 units on a scale
Phase 4 N=20 Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity
COVID-19
Primary: Plasma Viscosity — 2.35; 2.47; 1.61; 2.47 cP
Phase 4 N=42 Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
Schizophrenia · Schizo Affective Disorder · Schizoaffective Disorder
Primary: Prepulse Inhibition (PPI) — 32.45; 26.85; 14.11; 11.78 % inhibition of startle
Phase 4 N=90 Mixture of Liposomal Bupivacaine and Bupivacaine for TAP Block for Open Hysterectomy
Hysterectomy
Primary: Total Opioid Consumption During the First 72 Hours Postoperatively as Measured in Morphine Equivalents (mg) — 208; 203; 202 mg morphine equivalents
Phase 4 N=20 Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients
Shock, Surgical · Shock · Hypotension and Shock
Primary: Duration of ATII Vasopressor Usage in the Intraoperative Setting — 1 hours
Phase 4 N=43 Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE
HIV-1-infection
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm — 32 Participants
Phase 4 N=140 Oxytocin Dosage to Decrease Induction Duration
Obesity · Labor, Induced · Oxytocin
Primary: Length of Time to Delivery — 796; 694; 715; 762 minutes
Phase 4 N=123 A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Change From Baseline in the Composite Score of BME, Synovitis, and Tenosynovitis Assessed by PsAMRIS at Week 24 — -2.32 score on a scale
Phase 4 N=46 Esthetic Outcomes Following Immediate Implant Combine With Soft Tissue Augmentation
Dental Implant · Immediate Dental Implant · Soft Tissue Augmentation
Primary: Change in Ridge Dimension — -1.65; -1.87; -1.44; -1.37 millimeters (mm)
Phase 4 N=199 Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen
Pelvic Organ Prolapse · Urogenital Prolapse · Vaginal Vault Prolapse
Primary: Surgical "Failure" Defined by (i) Anatomic Assessment of Prolapse, (ii) Presence of Bulge Symptoms, and/or (Iii) Retreatment of Prolapse — 18; 8 Participants
Phase 4 N=246 A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
Hypogonadism
Primary: Change From Baseline to End of Treatment (EOT) in 24-hour Average Systolic Blood Pressure (SBP) — 1.9 mmHg
Phase 4 N=40 Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Parkinson's Disease
Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale
Phase 4 N=20 Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
Renal Transplant Rejection
Primary: Antibody and T Cell-mediated Immune Response — 17; 0; 0; 1 participants
Phase 4 N=186 A Treatment for Severe Inflammatory Acne Subjects
Acne Vulgaris
Primary: Change in Number of Inflammatory Lesions — -30.1 Inflammatory lesions